Skip to main content
Monday, November 16, 2026Nov 16

Alzheimer’s drug gets FDA panel’s backing, setting the stage for broader use

FILE - This Dec. 21, 2022, image provided by Eisai in January 2023 shows vials and packaging for their medication Leqembi. On Friday, June 9, 2023, health advisers backed the full approval of the closely watched Alzheimer’s drug, a key step toward opening insurance coverage to U.S. seniors with early stages of the brain-robbing disease. (Eisai via AP, File)
FILE - This Dec. 21, 2022, image provided by Eisai in January 2023 shows vials and packaging for their medication Leqembi. On Friday, June 9, 2023, health advisers backed the full approval of the closely watched Alzheimer’s drug, a key step toward opening insurance coverage to U.S. seniors with early stages of the brain-robbing disease. (Eisai via AP, File)

WASHINGTON (AP) — Health advisers on Friday unanimously backed the full approval of a closely watched Alzheimer’s drug, a key step toward opening insurance coverage to U.S. seniors with early stages of the brain-robbing disease.

The drug, Leqembi, received conditional approval from the Food and Drug Administration in January based on early results suggesting it could slow Alzheimer’s progression by several months. The FDA now is reviewing more definitive results to decide whether the drug should receive the agency’s full endorsement.

The decision carries extra significance because insurers have held off on paying for the infused treatment until it has full FDA approval.

The FDA panel of outside advisers voted 6-0 that a large company study confirmed the drug’s benefits for patients with mild or early Alzheimer’s. The nonbinding vote amounts to a recommendation for full approval, and the FDA is scheduled to issue a final decision on the matter by July 6.

The FDA’s initial OK for Leqembi came via the agency’s accelerated approval program, which allows early access to drugs based on laboratory or biological measures suggesting that they might help patients. The drug, marketed by Eisai and Biogen, helped clear a brain plaque that is a hallmark of Alzheimer’s.